Date: 2014-07-08
Type of information: Grant
Company: Cynapsus Therapeutics (Canada)
Investors: The Michael J. Fox Foundation - MJFF (USA)
Amount: $0.5 million
Funding type: grant
Planned used: This second MJFF grant will be used to fund the Company’s CTH-105 clinical study. This study is planned to examine the effect of APL-130277, a new fast-acting reformulation of apomorphine for sublingual delivery, on relieving “off” episodes over a single day with a dose-titration used to determine dose strengths necessary for future clinical development. This pilot study will enroll patients with Parkinson’s disease who are naïve to the use of apomorphine and who experience at least one daily “off” episode with a total duration of “off” in any 24-hour period of at least 2 hours.
Others: * On July 8, 2014, Cynapsus Therapeutics announced that it has been awarded a new grant of US$500,000 from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to support clinical studies to develop APL-130277, a sublingual thin film strip reformulation of apomorphine. This second MJFF grant will be used to fund the Company’s CTH-105 clinical study. The MJFF previously awarded Cynapsus an initial grant of USD$947,925 to complete a comparative study of APL-130277 (i.e. CTH-103) versus subcutaneous injection. The results of the CTH-103 study were announced on January 13, 2014.
Therapeutic area: Neurodegenerative diseases
